Franco Vizeacoumar

Biography

Dr. Franco Vizeacoumar is currently working as a Adjunct Professor in the Department of Pharmacy, University of Saskatchewan , Canada. His research interests includes developing genotype-directed cancer therapy for solid tumors by applying a basic biological concept called synthetic lethality. In effect, any genetic alteration that can cause selective-lethality with an oncogenic or a tumor suppressor mutation can be potentially translated into a therapeutic target. This will ultimately enable personalized medicine in which patients having disease of similar biological origin will likely benefit from a specific drug treatment. Our long term goal is to build a synthetic lethal network that will enable us to understand the genetic dependencies of cancer cells and define key therapeutic targets.. He /she is serving as an editorial member and reviewer of several international reputed journals. Dr. Franco Vizeacoumar is the member of many international affiliations. He/ She has successfully completed his Administrative responsibilities. He /she has authored of many research articles/books related to developing genotype-directed cancer therapy for solid tumors by applying a basic biological concept called synthetic lethality. In effect, any genetic alteration that can cause selective-lethality with an oncogenic or a tumor suppressor mutation can be potentially translated into a therapeutic target. This will ultimately enable personalized medicine in which patients having disease of similar biological origin will likely benefit from a specific drug treatment. Our long term goal is to build a synthetic lethal network that will enable us to understand the genetic dependencies of cancer cells and define key therapeutic targets..

Research Interest

developing genotype-directed cancer therapy for solid tumors by applying a basic biological concept called synthetic lethality. In effect, any genetic alteration that can cause selective-lethality with an oncogenic or a tumor suppressor mutation can be potentially translated into a therapeutic target. This will ultimately enable personalized medicine in which patients having disease of similar biological origin will likely benefit from a specific drug treatment. Our long term goal is to build a synthetic lethal network that will enable us to understand the genetic dependencies of cancer cells and define key therapeutic targets.